Literature DB >> 9568675

Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line.

J E Perry1, M E Grossmann, D J Tindall.   

Abstract

BACKGROUND: The human prostate carcinoma cell line, LNCaP, proliferates under stimulation by a limited number of mitogenic signals, which include members of the growth factor and steroid hormone families. Androgens and epidermal growth factor (EGF) are among the LNCaP cell mitogens. We tested the hypothesis that these mitogens stimulate LNCaP cell proliferation at least in part through the induction of cyclin D1, a protein requisite for cell cycle progression, which is expressed in the G1 phase of the cell cycle.
METHODS: LNCaP cells were grown in serum-free medium with 10 ng/ml or 100 ng/ml EGF, 0.1 nM or 1.0 nM mibolerone (a potent androgen agonist), or vehicle (distilled water or 0.01% ethanol). Expression of cyclin D, mRNA, and protein were assessed by Northern and Western blot analyses. Transcription regulation was assessed by nuclear runoff assay.
RESULTS: Western analyses demonstrated that EGF stimulated cyclin D1 protein expression 4-fold over 12 hr. Northern analyses showed a 4-fold increase in mRNA expression, peaking within 4 hr of EGF stimulation. There were no effects on cyclin D1 protein or mRNA expression with mibolerone treatments. We further explored the mechanism of cyclin D1 induction. LNCaP cells stimulated for 1 hr with EGF demonstrated a 2-fold increase in cyclin D1 message, as assayed by nuclear runoff transcription assay. In addition, we demonstrated the involvement of the protein kinase C pathway in mediating the EGF induction of cyclin D1.
CONCLUSIONS: We conclude that one of the mechanisms by which growth factors such as EGF may stimulate prostate cell proliferation is through the direct induction of cyclin proteins, which are necessary for entry of cells into mitosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568675     DOI: 10.1002/(sici)1097-0045(19980501)35:2<117::aid-pros5>3.0.co;2-g

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  21 in total

1.  Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.

Authors:  Aimee K Bence; Eric B Anderson; Maqbool A Halepota; Michael A Doukas; Phillip A DeSimone; George A Davis; Deborah A Smith; Kevin M Koch; Andrew G Stead; Steve Mangum; Carolyn J Bowen; Neil L Spector; Showchien Hsieh; Val R Adams
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

2.  Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s).

Authors:  David A Foster; Paige Yellen; Limei Xu; Mahesh Saqcena
Journal:  Genes Cancer       Date:  2010-11

Review 3.  Cyclin D degradation by E3 ligases in cancer progression and treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  Semin Cancer Biol       Date:  2020-01-30       Impact factor: 15.707

Review 4.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

5.  Betacellulin ameliorates hyperglycemia in obese diabetic db/db mice.

Authors:  Yoon Sin Oh; Seungjin Shin; Hui Ying Li; Eun-Young Park; Song Mi Lee; Cheol Soo Choi; Yong Lim; Hye Seung Jung; Hee-Sook Jun
Journal:  J Mol Med (Berl)       Date:  2015-06-14       Impact factor: 4.599

6.  Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.

Authors:  H Swaisland; A Laight; L Stafford; H Jones; C Morris; A Dane; R Yates
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.

Authors:  Xiaoming Ju; Mathew C Casimiro; Michael Gormley; Hui Meng; Xuanmao Jiao; Sanjay Katiyar; Marco Crosariol; Ke Chen; Min Wang; Andrew A Quong; Michael P Lisanti; Adam Ertel; Richard G Pestell
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

Review 8.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

9.  Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt-mTORC1 pathway.

Authors:  Cong Cao; Xuesong Huang; Yuyuan Han; Yinsheng Wan; Lutz Birnbaumer; Geng-Sheng Feng; John Marshall; Meisheng Jiang; Wen-Ming Chu
Journal:  Sci Signal       Date:  2009-04-28       Impact factor: 8.192

10.  Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.

Authors:  Beverly Drucker; Jennifer Bacik; Michelle Ginsberg; Stephanie Marion; Paul Russo; Madhu Mazumdar; Robert Motzer
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.